Osteoarthritis (OA) of the knee remains a significant health issue, especially among those with excess body weight. Excess weight, combined with advancing age, is a leading risk factor contributing to the progression of this joint disorder. Recent findings suggest that weight loss can not only ease symptoms but also enhance overall physical function and quality of life.
In two pivotal phase 3 trials, participants administered retatrutide, a novel weight-loss treatment, demonstrated substantial improvements in both weight and knee pain. This injectable medication has drawn attention for its dual benefits in managing obesity and alleviating OA symptoms. One notable outcome was that nearly two-thirds of participants achieved weight loss exceeding 15%, which had a direct correlation with reported reductions in knee pain.
The trials involved over 1,000 participants who had both obesity and knee osteoarthritis, specifically excluding individuals with type 2 diabetes. Sponsored by Eli Lilly, the trials included randomized groups receiving varying doses of retatrutide — 9 mg and 12 mg in TRIUMPH-4, and 4 mg, 9 mg, or 12 mg in TRIUMPH-1-OA.
In TRIUMPH-4, lasting 68 weeks, the primary observed outcomes were changes in the WOMAC pain score and overall weight loss. Participants on retatrutide experienced significant reductions in pain scores: 3.96 points for the 9 mg dose and 3.74 points for the 12 mg dose. In contrast, those on placebo only saw a 2.12-point reduction. In terms of weight, individuals treated with retatrutide lost approximately 20%, significantly more than the 5% loss noted in the placebo group.
The subsequent TRIUMPH-1-OA trial extended for 80 weeks, further confirming these observations with pain score reductions of 3.22 (4 mg), 3.48 (9 mg), and 3.64 (12 mg) compared to a mere 1.87 reduction for the placebo group.
Mechanically, weight loss profoundly impacts the knee joint, with studies indicating that each pound of body weight translates to 2 to 5 pounds of force across the knee during essential movements such as walking or climbing stairs. According to Dr. Timothy Gibson, an orthopedic surgeon, losing one-fifth or more of body weight can significantly lower the mechanical stress on the knees, yielding notable pain reduction and improved mobility.
In addition to mechanical benefits, ongoing research suggests that obesity is intertwined with chronic, low-grade inflammation. Retatrutide's efficacy may also be attributed to its ability to reduce adipose tissue and improve metabolic health. By lowering levels of inflammatory substances produced by excess fat, it could help mitigate the progression of joint pain and damage.
The multifactorial nature of weight management and knee OA raises further questions about how retatrutide operates within the body. As a triple agonist, it influences GLP-1, GIP, and glucagon receptors. Such mechanisms may offer additional anti-inflammatory benefits beyond simple weight loss.
While clinical insights suggest a positive effect on knee pain from retatrutide, ongoing studies are essential to fully characterize its complete therapeutic landscape, including any potential long-term benefits or adverse effects that may arise from its use.
The trials do not yet yield definitive conclusions about broader applications since retatrutide awaits regulatory approval from the U.S. Food and Drug Administration. Several clinical questions remain, including how these findings will translate into routine clinical applications and the potential role of retatrutide in treating other obesity-related conditions. Further investigation will clarify its long-term efficacy, safety profile, and its impacts on joint health and function.
Continued vigilance in upcoming studies will provide deeper insights into the relationship between weight management therapies like retatrutide and successful outcomes for patients with knee osteoarthritis.